Immune responses of a meningococcal A + W outer membrane vesicle (OMV) vaccine with and without aluminium hydroxide adjuvant in two different mouse strains

APMIS

Volumn 124, Issue 11, 2016, Pages 996-1003

  Tunheim, Gro ^a   Arnemo, Marianne ^a,b   Næss, Lisbeth M ^a   Norheim, Gunnstein ^a   Garcia, Luis ^c   Cardoso, Daniel ^c   Mandiarote, Aleida ^c   Gonzalez, Domingo ^c   Sinnadurai, Kalpana ^a   Fjeldheim, Åse Karine ^a   Bolstad, Karin ^a   Rosenqvist, Einar ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c FINLAY INSTITUTE   (Cuba)

Author keywords

aluminium hydroxide; BALB c; C57BL 6; Meningococcal vaccine; outer membrane vesicles

Indexed keywords

ALUMINUM HYDROXIDE; DEOXYCHOLIC ACID; IMMUNOGLOBULIN G ANTIBODY; MENINGOCOCCAL A OUTER MEMBRANE VESICLE PROTEIN; MENINGOCOCCAL W OUTER MEMBRANE VESICLE PROTEIN; MENINGOCOCCUS VACCINE; NADA 2 PROTEIN; NADA 3 PROTEIN; OPCA PROTEIN; OUTER MEMBRANE PROTEIN; PORIN A; PORIN B2; PORIN B3; PROTEIN VARIANT; RMPM PROTEIN; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; MENINGOCOCCOSIS; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; TH1 CELL; TH2 CELL; AFRICA SOUTH OF THE SAHARA; ANIMAL; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MEMBRANE MICROPARTICLE;

ADJUVANTS, IMMUNOLOGIC; AFRICA SOUTH OF THE SAHARA; ALUMINUM HYDROXIDE; ANIMALS; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; CELL-DERIVED MICROPARTICLES; FEMALE; IMMUNOGLOBULIN G; MENINGOCOCCAL VACCINES; MICE, INBRED BALB C; MICE, INBRED C57BL; NEISSERIA MENINGITIDIS, SEROGROUP A; NEISSERIA MENINGITIDIS, SEROGROUP W-135;

EID: 84988416231     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12589     Document Type: Article

References (39)

1. Lapeyssonnie L. Cerebrospinal meningitis in Africa. Bull World Health Organ 1963;28(Suppl):1–114.
2. Greenwood B. Manson Lecture. Meningococcal meningitis in Africa. Trans R Soc Trop Med Hyg 1999;93:341–53.
3. Norheim G, Rosenqvist E, Aseffa A, Yassin MA, Mengistu G, Kassu A, et al. Characterization of Neisseria meningitidis isolates from recent outbreaks in Ethiopia and comparison with those recovered during the epidemic of 1988 to 1989. J Clin Microbiol 2006;44:861–71.
4. Norheim G, Rosenqvist E, Hoiby EA, Caugant DA. Comparison of serogrop A Neisseria meningitidis strains of sequence type 2859 emerging in Burkina Faso in meningitis seasons 2003 and 2004 with predominating ST-7 strains [abstract] 16th International Pathogenic Neisseria Conference 7-12 September. In: Proceedings of the 16th International Pathogenic Neisseria Conference 7-12 September 2008, 2008.
5. Caugant DA, Kristiansen PA, Wang X, Mayer LW, Taha MK, Ouedraogo R, et al. Molecular characterization of invasive meningococcal isolates from countries in the African meningitis belt before introduction of a serogroup A conjugate vaccine. PLoS One 2012;7:e46019.
6. Caugant DA, Nicolas P. Molecular surveillance of meningococcal meningitis in Africa. Vaccine 2007;25(Suppl 1):A8–11.
7. Nicolas P, Norheim G, Garnotel E, Djibo S, Caugant DA. Molecular epidemiology of neisseria meningitidis isolated in the African Meningitis Belt between 1988 and 2003 shows dominance of sequence type 5 (ST-5) and ST-11 complexes. J Clin Microbiol 2005;43:5129–35.
8. Funk A, Uadiale K, Kamau C, Caugant DA, Ango U, Greig J. Sequential outbreaks due to a new strain of Neisseria meningitidis serogroup C in northern Nigeria, 2013-14. PLoS Currents 2014;6: http://currents.plos.org/outbreaks/article/sequential-outbreaks-due-to-a-new-strain-of-neisseria-meningitidis-serogroup-c-in-northern-nigeria-2013-14/
9. Bjune G, Hoiby EA, Gronnesby JK, Arnesen O, Fredriksen JH, Halstensen A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093–6.
10. Tappero JW, Lagos R, Ballesteros AM, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999;281:1520–7.
11. Kelly C, Arnold R, Galloway Y, O'Hallahan J. A prospective study of the effectiveness of the New Zealand meningococcal B vaccine. Am J Epidemiol 2007;166:817–23.
12. Norheim G, Tunheim G, Naess LM, Kristiansen PA, Caugant DA, Rosenqvist E. An outer membrane vesicle vaccine for prevention of serogroup A and W-135 meningococcal disease in the African meningitis belt. Scand J Immunol 2012;76:99–107.
13. Tunheim G, Arnemo M, Næss LM, Fjeldheim ÅK, Nome L, Bolstad K, et al. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines. Vaccine 2013;31:6097–106.
14. Garcia L, Valera R, Perez S, Rodriguez M, Tunheim G, Cuevas I, et al. P46 Safety and immunogenicity of a serogroup A and W meningococcal outer membrane vesicle vaccine: Results from a Phase I clinical study in Cuban volunteers. In: Proceedings of the Nineteenth International Pathogenic Conference. Asheville, North Carolina, USA, 2014.
15. Naess LM, Aase A, Norheim G, Tunheim G, Fjeldheim ÅK, Bolstad K, et al. P42 Antibody responses in humans after vaccination with a novel serogroup A and W outer membrane vesicle (OMV) vaccine targeted for the African meningitis belt – results from a phase I study in Cuba. In: Proceedings of the Nineteenth International Pathogenic Conference. Asheville, North Carolina, USA, 2014.
16. Fredriksen JH, Rosenqvist E, Wedege E, Bryn K, Bjune G, Froholm LO, et al. Production, characterization and control of MenB-vaccine “Folkehelsa”: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Annals 1991;14:67–79; discussion -80.
17. Hosking J, Rasanathan K, Mow FC, Jackson C, Martin D, O'Hallahan J, et al. Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteens. Clin Vaccine Immunol 2007;14:1393–9.
18. Bai X, Findlow J, Borrow R. Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles. Expert Opin Biol Ther 2011;11:969–85.
19. EMA. European medicines agency summary of product characteristics Bexsero. 2012-01-28
20. Rosenqvist E, Hoiby EA, Bjune G, Aase A, Halstensen A, Lehmann AK, et al. Effect of aluminium hydroxide and meningococcal serogroup C capsular polysaccharide on the immunogenicity and reactogenicity of a group B Neisseria meningitidis outer membrane vesicle vaccine. Dev Biol Stand 1998;92:323–33.
21. Sanders H, Feavers IM. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines. Expert Rev Vaccines 2011;10:323–34.
22. Watanabe H, Numata K, Ito T, Takagi K, Matsukawa A. Innate immune response in Th1- and Th2-dominant mouse strains. Shock 2004;22:460–6.
23. Pollard AJ, Galassini R, Rouppe van der Voort EM, Hibberd M, Booy R, Langford P, et al. Cellular immune responses to Neisseria meningitidis in children. Infect Immun 1999;67:2452–63.
24. Garcia L, Mandiarote A, Norheim G, Gonzalez D, Reyes G, Tunheim G, et al. P227 Scale-up of process for GMP production of a serogroup A and W135 meningococcal outer membrane vesicle vaccine for Africa [abstract]. In: Proceedings of the 17th International Pathogenic Conference. Banff, Alberta, Canada 2010.
25. Wedege E. Immunoblot analysis of sera from patients and vaccinees. Methods Mol Med 2001;66:275–88.
26. Norheim G, Aseffa A, Yassin MA, Mengistu G, Kassu A, Fikremariam D, et al. Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci. Clin Vaccine Immunol 2008;15:863–71.
27. Maslanka SE, Gheesling LL, Libutti DE, Donaldson KB, Harakeh HS, Dykes JK, et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clin Diagn Lab Immunol 1997;4:156–67.
28. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009;27(Suppl 2):B112–6.
29. Mirlashari MR, Lyberg T. Expression and involvement of Toll-like receptors (TLR)2, TLR4, and CD14 in monocyte TNF-alpha production induced by lipopolysaccharides from Neisseria meningitidis. Med Sci Monit 2003;9:Br316–24.
30. Acevedo R, Fernandez S, Zayas C, Acosta A, Sarmiento ME, Ferro VA, et al. Bacterial outer membrane vesicles and vaccine applications. Front Immunol 2014;5:121.
31. Romeu B, Lastre M, Garcia L, Cedre B, Mandariote A, Farinas M, et al. Combined meningococcal serogroup A and W outer-membrane vesicles activate cell-mediated immunity and long-term memory responses against non-covalent capsular polysaccharide A. Immunol Res 2013;58:75–85.
32. Giuliani MM, Biolchi A, Serruto D, Ferlicca F, Vienken K, Oster P, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010;28:5023–30.
33. Awate S, Babiuk LA, Mutwiri G. Mechanisms of action of adjuvants. Front Immunol 2013;4:114.
34. Marrack P, McKee AS, Munks MW. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009;9:287–93.
35. Frasch CE, Zahradnik JM, Wang LY, Mocca LF, Tsai CM. Antibody response of adults to an aluminum hydroxide-adsorbed Neisseria meningitidis serotype 2b protein-group B polysaccharide vaccine. J Infect Dis 1988;158:710–8.
36. Wang LY, Frasch CE. Development of a Neisseria meningitidis group B serotype 2b protein vaccine and evaluation in a mouse model. Infect Immun 1984;46:408–14.
37. Shi Y, HogenEsch H, Regnier FE, Hem SL. Detoxification of endotoxin by aluminum hydroxide adjuvant. Vaccine 2001;19:1747–52.
38. Sellers RS, Clifford CB, Treuting PM, Brayton C. Immunological variation between inbred laboratory mouse strains: points to consider in phenotyping genetically immunomodified mice. Vet Pathol 2012;49:32–43.
39. Michaelsen TE, Kolberg J, Aase A, Herstad TK, Hoiby EA. The four mouse IgG isotypes differ extensively in bactericidal and opsonophagocytic activity when reacting with the P1.16 epitope on the outer membrane PorA protein of Neisseria meningitidis. Scand J Immunol 2004;59:34–9.